bioAffinity Tech Reports Leadership Changes, Comp Arrangements
Ticker: BIAFW · Form: 8-K · Filed: Jan 31, 2024 · CIK: 1712762
Complexity: simple
Sentiment: neutral
Topics: leadership-change, executive-compensation, corporate-governance
TL;DR
**bioAffinity Technologies just announced executive changes and new pay deals, watch for strategic shifts.**
AI Summary
bioAffinity Technologies, Inc. filed an 8-K on January 31, 2024, reporting an event that occurred on January 26, 2024, related to the departure or election of directors/officers and their compensatory arrangements. This filing also covers financial statements and exhibits. For investors, this matters because changes in leadership and executive compensation can signal shifts in company strategy, financial health, or governance, potentially impacting future stock performance.
Why It Matters
Changes in executive leadership and compensation can significantly influence a company's strategic direction and operational stability, directly affecting investor confidence and stock valuation.
Risk Assessment
Risk Level: medium — Changes in leadership can introduce uncertainty regarding future company direction and stability, posing a moderate risk to investors.
Analyst Insight
A smart investor would monitor subsequent filings or company announcements for specific details regarding the personnel changes and compensation structures, as these will provide clearer insights into the company's future direction and potential impact on its financial health.
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — the registrant filing the 8-K
- January 26, 2024 (date) — date of the earliest event reported
- January 31, 2024 (date) — date the 8-K was filed
Forward-Looking Statements
- The company will provide more details on the specific individuals involved in the leadership changes and their new compensatory arrangements in future filings or press releases. (bioAffinity Technologies, Inc.) — medium confidence, target: Q1 2024
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 26, 2024.
What specific items are covered in this 8-K filing by bioAffinity Technologies, Inc.?
This 8-K filing covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' and 'Financial Statements and Exhibits'.
What is the Central Index Key (CIK) for bioAffinity Technologies, Inc.?
The Central Index Key (CIK) for bioAffinity Technologies, Inc. is 0001712762.
Where is bioAffinity Technologies, Inc.'s principal executive office located?
bioAffinity Technologies, Inc.'s principal executive office is located at 22211 W Interstate 10 Suite 1206, San Antonio, Texas 78257.
What is the state of incorporation for bioAffinity Technologies, Inc.?
bioAffinity Technologies, Inc. is incorporated in Delaware.
Filing Stats: 991 words · 4 min read · ~3 pages · Grade level 12.5 · Accepted 2024-01-31 16:05:25
Key Financial Figures
- $75,000 — even Girgenti for calendar year 2023 of $75,000, $100,000, $100,000, $21,000, $52,500 a
- $100,000 — enti for calendar year 2023 of $75,000, $100,000, $100,000, $21,000, $52,500 and $37,500
- $21,000 — ar 2023 of $75,000, $100,000, $100,000, $21,000, $52,500 and $37,500, respectively to b
- $52,500 — f $75,000, $100,000, $100,000, $21,000, $52,500 and $37,500, respectively to be paid 50
- $37,500 — 100,000, $100,000, $21,000, $52,500 and $37,500, respectively to be paid 50% in cash an
Filing Documents
- form8-k.htm (8-K) — 47KB
- ex10-1.htm (EX-10.1) — 66KB
- ex10-2.htm (EX-10.2) — 13KB
- 0001493152-24-004490.txt ( ) — 357KB
- biaf-20240126.xsd (EX-101.SCH) — 4KB
- biaf-20240126_def.xml (EX-101.DEF) — 26KB
- biaf-20240126_lab.xml (EX-101.LAB) — 36KB
- biaf-20240126_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOAFFINITY TECHNOLOGIES, INC. By: /s/ Maria Zannes Maria Zannes President and Chief Executive Officer Dated: January 31, 2024